Skip to main content
Fig. 1 | Orphanet Journal of Rare Diseases

Fig. 1

From: Long-term health-related quality of life in patients treated with subcutaneous C1-inhibitor replacement therapy for the prevention of hereditary angioedema attacks: findings from the COMPACT open-label extension study

Fig. 1

COMPACT open-label study design and timing of HRQoL assessments. AE-QoL Angioedema Quality of Life Questionnaire, C1-INH(SC) subcutaneous C1-inhibitor, EQ-5D European Quality of Life-5 Dimensions Questionnaire, HADS Hospital Anxiety and Depression Scale, HAE-QoL Hereditary Angioedema Quality of Life Questionnaire, HRQoL health-related quality of life, TSQM Treatment Satisfaction Questionnaire for Medication, TP treatment period, US United States, WPAI Work Productivity and Activity Impairment Questionnaire

Back to article page